



Ifa

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/731,769
	Filing Date	December 9, 2003
	First Named Inventor	Robert A. Kirken, et al.
	Art Unit	1614
	Examiner Name	Unassigned
Total Number of Pages in This Submission	Attorney Docket Number	2105-00401


ENCLOSURES <i>(check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> <ul style="list-style-type: none">• Form PTO-1449 <i>(w/copies of cited art)</i>• Acknowledgement Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm	CONLEY ROSE, P. C.	
Signature		
Printed name	Carol G. Mintz	
Date	May 6, 2005	Reg. No. 38,561

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or Printed Name	Janna M. Melasecca	
Signature		Date May 6, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and selection option 2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/731,769 Confirmation No. 4261
Applicant : Robert A. Kirken, et al.
Filed : December 9, 2003
For : Methods for Selectively Inhibiting Janus Tryosine Kinase 3 (JAK3)
TC/A.U. : 1614
Examiner : Unassigned

Customer No.: 23505
Atty. Dkt. No.: 2105-00401
Date: May 6, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450


Sir:

This Information Disclosure Statement, including completed Form PTO-1449, comprises a list of pertinent art of which Applicants are aware.

The submission of this Information Disclosure Statement and the references submitted therewith is not an admission that the art cited is "prior" with respect to the present invention, nor is it a representation, that no better art exists. Applicants hereby reserve the right to swear behind or otherwise disprove any alleged "prior" nature of any art cited should the facts support and the situation warrant such an action. It is submitted that the art cited does not constitute a bar to the patentability of Applicants' invention under 35 U.S.C. § 102 or § 103.

No Office Action on the merits has been received in the present application. In the event that an Office Action dated prior to the mailing date of this Information Disclosure Statement has been issued, please charge Deposit Account 03-2769, Conley Rose, P.C., in the amount of \$180, so that this Information Disclosure Statement may be considered under Rule 1.97(c).


Respectfully submitted,



Carol G. Mintz
Reg. No. 38,561
CONLEY, ROSE, P.C.
P. O. Box 3267
Houston, Texas 77253-3267
(713) 238-8000
AGENT FOR APPLICANTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.
2105-00401Serial No.
10/731,769Applicant
Robert A. KIRKEN et al.Filing Date
December 9, 2003Group
1614**REFERENCE DESIGNATION U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	2002/0042513		Uckun et al.			
	AB	2002/0032204		Moon et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	Translation	
							YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AC	PCT/US03/38993 International Search Report dated 24 May 2004
	AD	Database EMBASE on STN Online, No. 2003366614, KAHAN et al. "New Approaches of Transplant Immunosuppression," abstract, Transplantation Proceedings, 2003, 35/5, pp. 1621-1623
	AE	Database EMBASE on STN Online, No. 2003391451, MANEZ, R. "Current Trends in Transplantation and Immunosuppressive Treatment," abstract, Drug News and Perspective, 2003, 16/5, pp. 332-336.
	AF	Database CAPLUS on STN Online, No. 1993:603032, DIMMOCK et al. "Evaluation of Some Mannich Bases of Cycloalkanones and Related Compounds For Cytotoxic Activity," abstract, European Journal of Medicinal Chemistry, 1993, 28(4), pp. 313-22.
	AG	Database CAPLUS on STN Online, No. 1995:962281, DIMMOCK et al. "Synthesis and Cytotoxic Evaluation of Some Mannich Bases of Alicyclic Ketones," abstract, Pharmazie, 1995, 50(1), pp. 668-71.
	AH	Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol. (2000) 12:242-249.
	AI	Denton, MD, et al.. Immunosuppressive strategies in transplantation. Lancet (1999) 353:1083-1091.
	AJ	Mihatsch MJ, et al. The side effects of Ciclosporin-A and Tacrolimus. (1998) Clin. Nephrol 49 (6):356-363.
	AK	Kirken RA, Stepkowski SM. New directions in T-cell signal transduction and transplantation tolerance. Curr Opin in Organ Transplant (2002) 7:18-25.
	AL	Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. (1994) 76:263-274.
	AM	Irving BA, et al. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med. (1993) 177:1093-1103.
	AN	Chan AC, et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science. (1994) 264:1599-1601.
	AO	Appleby MW, et al. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. (1992) 70:751-763.
	AP	Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol. (1999) 17:149-187.
	AQ	Leonard WJ, O'Shea JJ. JAKs and STATs: biological implications. Annu Rev Immunol. (1998);16:293-322.
	AR	Kondo M, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. (1993) 262:1874-1877.
	AS	Noguchi M, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. (1993);262:1877-1880.

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Atty. Docket No.
2105-00401

Serial No.
10/731,769

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Robert A. KIRKEN et al.

Filing Date	Group
December 9, 2003	1614

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.</p>	